Highlights Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
0.89 ^USD	-3.26%		-9.18%	-31.54%

05-08	Enveric Biosciences, Inc. Announces Signing of Non-Binding Term Sheet with Undisclosed License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids	CI
03-26	Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enveric Biosciences, Inc. Announces Signing of Non-Binding Term Sheet with Undisclosed License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids	05-08	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Sector Update: Health Care Stocks Rise Late Afternoon	03-19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	03-19	MT
Enveric Biosciences Signs Licensing Term Sheets for Joint Disease Treatment Compounds; Shares Rise	03-19	MT
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease	03-19	CI
Enveric Biosciences Surging on Plans to Sell Cannabinoid IP Portfolio, Focus Shift to Psilocin Therapies	02-23	MT
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders	02-21	CI
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series	01-03	CI
Health Care Up on Defensive Bias -- Health Care Roundup	12-28	DJ
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series	12-28	CI
Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds	12-05	CI
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry	11-27	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373	23-10-18	CI
Enveric Biosciences Secures US Patent for EB-373 for Anxiety Disorder Treatment	23-08-28	MT
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program	23-08-21	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373	23-07-24	CI
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373	23-07-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Highlights

Filters